TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer
This is a single-arm, multicentre real-world observational study of TAS-102 in combination with regorafenib or fruquintinib for third-line and above advanced colorectal cancer.
TAS 102|Regorafenib|Fruquintinib|Gastrointestinal Tumours
DRUG: regorafenib|DRUG: fruquintinib
Progression-free Survival (PFS), PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first., one year
Objective Response Rate (ORR), ORR, determined using RECIST v1.1, defined as best overall response (CR or PR) across all assessment time points during the period from enrolment to termination of trial treatment., one year|Disease Control Rate (DCR), Determined using RECIST v1.1 criteria., one year|Incidence and severity of adverse events (AE) and serious adverse events (SAE), Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0., two years
This is a single-arm, multicentre real-world observational study of TAS-102 in combination with regorafenib or fruquintinib for third-line and above advanced colorectal cancer.The purpose of the study is to evaluate the efficacy and safety of TAS-102 in combination with a regimen of regorafenib or fruquintinib for the treatment of advanced colorectal cancer in the third line and above.